Մալթա - անգլերեն - Malta Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 mg - antibacterials for systemic use

Մալթա - անգլերեն - Malta Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 g - antibacterials for systemic use

Մալթա - անգլերեն - Malta Medicines Authority

dali pharma gmbh brehmstrasse 56, 40239, dusseldorf,, germany - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 g - antibacterials for systemic use

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime;  ;   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to 1 g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

viatris limited - ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime;  ;   - powder for injection - 2 g - active: ceftazidime pentahydrate 2.328 g equivalent to 2g ceftazidime     excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other ?- lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available. indications include: severe infections: for example: - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary, and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

Իսրայել - անգլերեն - Ministry of Health

vitamed pharmaceutical industries ltd - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1.000 g/vial - ceftazidime - ceftazidime-vit is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria.ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

multichem nz limited - ceftazidime pentahydrate 1160mg equivalent to ceftazidime 1000 mg - powder for injection - 1 g - active: ceftazidime pentahydrate 1160mg equivalent to ceftazidime 1000 mg excipient: sodium carbonate

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

multichem nz limited - ceftazidime pentahydrate 2320mg equivalent to ceftazidime 2000 mg - powder for injection - 2 g - active: ceftazidime pentahydrate 2320mg equivalent to ceftazidime 2000 mg excipient: sodium carbonate

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

sandoz inc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. ceftazidime for injection, usp may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. the dose depends on the severity of the infection and the patient’s condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime f

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

sagent pharmaceuticals - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 6 g in 30 ml - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae , including ampicillin-resistant strains; klebsiella spp.; enterobacter spp.; proteus mirabilis; escherichia coli; serratia spp.; citrobacter spp.; streptococcus pneumoniae; and staphylococcus aureus (methicillin-susceptible strains). - skin and skin-structure infections caused by pseudomonas aeruginosa; klebsiella spp.; escherichia coli; proteus spp., including proteus mirabilis and indole-positive proteus; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible strains); and streptococcus pyogenes (group a beta-hemolytic streptococci). - urinary tract infections , both complicated and uncomplicated, caused by pseudomonas aeruginosa; enterobacter s